TORONTO, April 3, 2012 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign") announced today that, subject to receipt of approval of the TSX Venture Exchange, it has issued from treasury 500,000 common shares of Biosign to one of its directors in consideration of past services rendered to Biosign. Such shares will be subject to a four-month hold period in accordance with applicable securities laws.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information:
Scott Jenkins, CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
Email: [email protected]
Kosta Triantos
Bay Street Connect
Phone: (416) 900-3230
Email: [email protected]
Share this article